Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CLRB | 45.34% | $13.37M | -89.44% | 0.00% |
PLAY | 35.19% | $1.05B | -23.03% | 0.00% |
ANAB | 33.62% | $686.92M | -5.73% | 0.00% |
ARVN | 31.69% | $569.33M | -69.83% | 0.00% |
AGIO | 31.69% | $1.95B | -22.84% | 0.00% |
IBRX | 31.06% | $2.46B | -57.34% | 0.00% |
OVID | 29.99% | $24.39M | -52.78% | 0.00% |
IMNM | 29.58% | $764.84M | -26.57% | 0.00% |
YMAB | 29.48% | $217.42M | -61.07% | 0.00% |
ARWR | 28.60% | $2.22B | -37.45% | 0.00% |
AUTL | 27.72% | $614.79M | -30.63% | 0.00% |
GBIO | 27.25% | $23.80M | -87.54% | 0.00% |
RXRX | 26.92% | $2.20B | -28.71% | 0.00% |
CRSP | 26.49% | $4.03B | -15.67% | 0.00% |
VRA | 26.47% | $58.38M | -65.79% | 0.00% |
ENTA | 26.19% | $160.54M | -40.73% | 0.00% |
VEEV | 26.07% | $45.95B | +51.87% | 0.00% |
RGNX | 25.59% | $440.90M | -24.76% | 0.00% |
CGON | 25.28% | $1.99B | -13.82% | 0.00% |
FATE | 25.27% | $126.10M | -66.31% | 0.00% |
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the appointment of Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer. Dr. Sipos succeeds Jason Campagna, M.D., Ph.D., who will be departing the company.
Yahoo
OXB has acquired the remaining 10% stake in its US subsidiary from Q32 Bio (QTTB), bringing its ownership, as planned, to 100%. As previously disclosed in the Company’s Preliminary Results on 9 April, OXB US exercised its call option on 1 March to acquire the final 10% interest in OXB US from Q32. The stake was originally held by Homology Medicines, which merged with Q32 in 2024. The transfer of Q32’s 10% holding to OXB US, means that OXB US is now wholly owned by OXB. OXB US was originally esta
Yahoo
OXB completes acquisition of remaining stake in US subsidiary Progression to full ownership aligns with global strategy and supports long-term growth in the viral vector manufacturing market Oxford, UK – 23 June 2025: OXB (LSE: OXB) (“the Company”), a global quality and innovation-led cell and gene therapy CDMO, today announces that it has acquired the remaining 10% stake in its US subsidiary from Q32 Bio, Inc. (Q32), bringing its ownership, as planned, to 100%. As previously disclosed in the Co
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today reported financial results for the quarter ended March 31, 2025, and provided recent corporate updates.
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that the United States Food and Drug Administration ("FDA") has granted Fast Track designation (FTD) to Q32 Bio's bempikibart (ADX-914) for the treatment of AA. Bempikibart is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking IL-7 and TSLP signalin
Yahoo
Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced that the Company has dosed the first patients in both the Part A open-label extension (OLE) and Part B of the SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in patients with alopecia areata (AA).
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
LQDT | -15.44% | $739.31M | +16.42% | 0.00% |
CRK | -13.54% | $8.32B | +168.94% | 0.00% |
RLX | -12.53% | $2.00B | +18.92% | 0.45% |
SFIX | -11.69% | $478.88M | -9.61% | 0.00% |
XGN | -11.52% | $152.81M | +277.84% | 0.00% |
GIFI | -8.13% | $110.32M | +11.48% | 0.00% |
AR | -7.88% | $12.70B | +25.35% | 0.00% |
RRC | -7.84% | $9.78B | +22.05% | 0.83% |
EQT | -7.62% | $34.81B | +55.98% | 1.09% |
REVG | -7.04% | $2.23B | +84.15% | 0.48% |
FIGS | -7.02% | $946.05M | +11.28% | 0.00% |
DFDV | -6.98% | $264.45M | +1,862.19% | 0.00% |
FSP | -6.17% | $177.10M | +13.24% | 2.37% |
LOMA | -6.03% | $1.34B | +64.09% | 0.00% |
BULL | -5.67% | $5.22B | +1.78% | 0.00% |
DOGZ | -5.49% | $369.95M | +57.76% | 0.00% |
TW | -5.38% | $30.43B | +33.69% | 0.31% |
ANGO | -4.60% | $400.79M | +66.44% | 0.00% |
LXRX | -4.48% | $337.50M | -46.59% | 0.00% |
CIG.C | -4.44% | $2.55B | +19.87% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DBO | 0.01% | $224.00M | 0.77% |
PALL | -0.02% | $494.87M | 0.6% |
STOT | 0.03% | $253.88M | 0.45% |
IBTH | -0.06% | $1.60B | 0.07% |
THTA | 0.10% | $35.65M | 0.49% |
IBMN | -0.17% | $446.95M | 0.18% |
AGGH | 0.22% | $323.99M | 0.29% |
VGSH | 0.30% | $22.80B | 0.03% |
IBTI | -0.34% | $1.06B | 0.07% |
BSMW | -0.40% | $107.14M | 0.18% |
PTBD | 0.53% | $137.92M | 0.6% |
PHDG | 0.54% | $88.88M | 0.39% |
DBC | -0.57% | $1.21B | 0.87% |
PDBC | -0.62% | $4.37B | 0.59% |
BUXX | 0.66% | $318.71M | 0.25% |
DEFI | 0.75% | $14.62M | 0.94% |
JAAA | 0.77% | $21.75B | 0.2% |
LDUR | -0.78% | $929.55M | 0.5% |
OILK | -0.81% | $71.89M | 0.69% |
BNO | -0.99% | $103.68M | 1% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CTA | -16.03% | $1.06B | 0.76% |
TAIL | -11.49% | $99.76M | 0.59% |
SHYM | -11.08% | $349.95M | 0.35% |
IVOL | -10.58% | $351.30M | 1.02% |
UNG | -10.54% | $359.91M | 1.06% |
VIXY | -10.32% | $165.69M | 0.85% |
UUP | -10.23% | $237.02M | 0.77% |
USDU | -9.40% | $162.92M | 0.5% |
BTAL | -8.54% | $296.79M | 1.43% |
KMLM | -7.36% | $186.80M | 0.9% |
CANE | -7.20% | $10.44M | 0.29% |
FTSD | -6.75% | $231.79M | 0.25% |
TDTT | -5.65% | $2.63B | 0.18% |
STPZ | -5.20% | $450.22M | 0.2% |
UGA | -4.06% | $72.51M | 0.97% |
TPMN | -4.02% | $30.77M | 0.65% |
STIP | -3.91% | $12.71B | 0.03% |
JUCY | -3.73% | $271.76M | 0.6% |
DBE | -3.18% | $51.16M | 0.77% |
TBLL | -2.87% | $2.14B | 0.08% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TDS | 0.01% | $3.99B | +73.45% | 0.46% |
TPR | 0.02% | $17.91B | +107.21% | 1.62% |
IFRX | -0.02% | $55.90M | -50.14% | 0.00% |
ECG | 0.04% | $3.16B | +26.43% | 0.00% |
CIG | 0.08% | $3.64B | +9.32% | 0.00% |
SPT | 0.10% | $1.18B | -40.39% | 0.00% |
CRC | 0.10% | $4.07B | -13.22% | 3.39% |
CRESY | 0.11% | $663.20M | +29.03% | 5.69% |
CLMT | -0.15% | $1.35B | -3.64% | 0.00% |
CARM | -0.16% | $16.98M | -68.25% | 0.00% |
AIFU | 0.17% | $5.12B | +52.50% | 0.00% |
RPTX | -0.19% | $60.48M | -58.28% | 0.00% |
LW | 0.21% | $7.51B | -36.26% | 2.74% |
PRM | -0.22% | $2.06B | +81.75% | 0.00% |
SUZ | -0.22% | $11.62B | -6.95% | 0.00% |
ZCMD | -0.23% | $30.56M | -5.47% | 0.00% |
TGS | -0.23% | $1.89B | +40.79% | 0.00% |
SE | -0.24% | $86.62B | +112.74% | 0.00% |
BRFS | -0.24% | $5.78B | -7.69% | 0.00% |
UVV | 0.24% | $1.47B | +24.96% | 5.50% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ARKG | 28.91% | $1.05B | 0.75% |
XBI | 27.78% | $4.95B | 0.35% |
GNOM | 27.48% | $44.21M | 0.5% |
IBB | 25.64% | $5.36B | 0.45% |
PINK | 25.31% | $133.06M | 0.5% |
PBE | 24.69% | $223.16M | 0.58% |
XPH | 24.49% | $149.79M | 0.35% |
SCYB | 23.27% | $1.16B | 0.03% |
HYLB | 22.68% | $3.92B | 0.05% |
BSJP | 22.43% | $860.29M | 0.43% |
IWC | 22.28% | $824.65M | 0.6% |
BBHY | 22.23% | $595.73M | 0.07% |
SJNK | 22.13% | $4.63B | 0.4% |
EPHE | 22.08% | $110.18M | 0.59% |
ARKX | 22.00% | $329.95M | 0.75% |
JNK | 21.88% | $7.94B | 0.4% |
HYG | 21.82% | $17.62B | 0.49% |
RSPH | 21.69% | $727.92M | 0.4% |
FBT | 21.67% | $1.01B | 0.54% |
PID | 21.56% | $831.47M | 0.53% |
Current Value
$1.511 Year Return
Current Value
$1.511 Year Return